- Home
- CSTL vs SLDP Comparison
CSTL vs SLDP Comparison
Compare CSTL & SLDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- SLDP
- Stock Information
- Founded
- CSTL 2007
- SLDP 2011
- Country
- CSTL United States
- SLDP United States
- Employees
- CSTL N/A
- SLDP N/A
- Industry
- CSTL Medical Specialities
- SLDP Electrical Products
- Sector
- CSTL Health Care
- SLDP Energy
- Exchange
- CSTL Nasdaq
- SLDP Nasdaq
- Market Cap
- CSTL 661.7M
- SLDP 645.4M
- IPO Year
- CSTL 2019
- SLDP N/A
- Fundamental
- Price
- CSTL $22.14
- SLDP $6.34
- Analyst Decision
- CSTL Strong Buy
- SLDP Strong Buy
- Analyst Count
- CSTL 6
- SLDP 1
- Target Price
- CSTL $37.67
- SLDP $4.00
- AVG Volume (30 Days)
- CSTL 296.4K
- SLDP 17.9M
- Earning Date
- CSTL 11-03-2025
- SLDP 11-06-2025
- Dividend Yield
- CSTL N/A
- SLDP N/A
- EPS Growth
- CSTL N/A
- SLDP N/A
- EPS
- CSTL N/A
- SLDP N/A
- Revenue
- CSTL $346,269,000.00
- SLDP $22,667,000.00
- Revenue This Year
- CSTL N/A
- SLDP $27.38
- Revenue Next Year
- CSTL N/A
- SLDP $37.97
- P/E Ratio
- CSTL N/A
- SLDP N/A
- Revenue Growth
- CSTL 20.40
- SLDP 14.83
- 52 Week Low
- CSTL $14.59
- SLDP $0.68
- 52 Week High
- CSTL $35.84
- SLDP $8.05
- Technical
- Relative Strength Index (RSI)
- CSTL 46.56
- SLDP 62.73
- Support Level
- CSTL $22.16
- SLDP $5.94
- Resistance Level
- CSTL $23.19
- SLDP $8.05
- Average True Range (ATR)
- CSTL 0.89
- SLDP 0.90
- MACD
- CSTL -0.16
- SLDP 0.15
- Stochastic Oscillator
- CSTL 10.05
- SLDP 63.28
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About SLDP Solid Power Inc.
Solid Power Inc is engaged in solid-state battery technology and manufacturing processes. Its core technology is a sulfide-based solid electrolyte material, which replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells. Its commercialization plan is to manufacture and sell electrolytes to Tier 1 battery manufacturers and automotive original equipment manufacturers (OEMs) that choose to produce its battery cells.